Sovaldi (sofosbuvir) / Gilead 
Welcome,         Profile    Billing    Logout  
 18 Diseases   22 Trials   22 Trials   2501 News 


«12...10111213141516171819202122»
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead, yimitasvir (DAG181) / Dongguan HEC TaiGen Biopharma, HEC Pharm
    Enrollment closed:  Phase 3 Study of Yimitasvir Phosphate Capsules (clinicaltrials.gov) -  Apr 10, 2019   
    P3,  N=362, Active, not recruiting, 
    No abstract available Not yet recruiting --> Active, not recruiting
  • ||||||||||  ravidasvir (PPI-668) / Presidio Pharmaceuticals, Inc, Ascletis, Pharco Pharmaceuticals, Sovaldi (sofosbuvir) / Gilead
    Journal:  A new potent NS5A inhibitor in the management of hepatitis C virus: ravidasvir. (Pubmed Central) -  Apr 3, 2019   
    ...It is a potent NS5A inhibitor that was formerly known as PPI-668...Even more, HCV variants that had reduced susceptibility to ravidasvir are completely susceptible to other DAA. Finally, a large multicenteric registrational phase 3 clinical trial that included large percentages of difficult to treat patients (such as cirrhotic and interferon experienced patients) has been fully accomplished and proved high sustained virologic response rates (SVR12) rates with well acceptable safety and tolerability profiles in management of genotype 4 HCV patients.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy. (Pubmed Central) -  Mar 27, 2019   
    We review the evidence supporting possible mechanisms of lymphomagenesis after successful hepatitis C therapy, particularly involving late "second-hit" mutations after viral-induced DNA damage and antiviral therapy facilitating the emergence of latent malignant B-cell clones by decreasing local inflammation and immune surveillance. More reports may help elucidate any association between hepatitis C antiviral therapy and late lymphoid malignancies.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Trial completion date:  Management of Decompensated HCV Cirrhotic Patients (clinicaltrials.gov) -  Dec 5, 2018   
    P=N/A,  N=80, Completed, 
    Recruiting --> Active, not recruiting Trial completion date: Jan 2018 --> Jun 2018
  • ||||||||||  ribavirin / Generic mfg., Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Editorial for Esteban et al. (Pubmed Central) -  Oct 16, 2018   
    Active, not recruiting --> Enrolling by invitation | Trial completion date: Mar 2019 --> Aug 2019 No abstract available
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead, yimitasvir (DAG181) / Dongguan HEC TaiGen Biopharma, HEC Pharm
    Trial completion:  Phase 2 Study of Yimitasvir Phosphate Capsules (clinicaltrials.gov) -  Aug 22, 2018   
    P2,  N=129, Completed, 
    Initiation date: Jun 2018 --> Oct 2018 Active, not recruiting --> Completed
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal:  Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road? (Pubmed Central) -  May 11, 2018   
    Rituximab, either alone or in combination with DAA, has also been shown to be effective...As with non-MC related HCV, undoubtedly long term outcome data will be forthcoming over the next few years. As we move forward successful therapy of HCV is not likely to be a challenge in contrast to access to therapy.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Enrollment closed, Phase classification:  Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C (clinicaltrials.gov) -  May 4, 2018   
    P=N/A,  N=71, Active, not recruiting, 
    Accompanied by high efficacy, the favourable effect of treatment on PROs improves patients' experience in this difficult-to-treat population with HCV. Recruiting --> Active, not recruiting | Phase classification: P4 --> PN/A
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, Sovaldi (sofosbuvir) / Gilead
    Enrollment closed, Trial completion date, Trial primary completion date:  Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects (clinicaltrials.gov) -  Apr 18, 2018   
    P3b,  N=215, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Phase classification: P4 --> PN/A Recruiting --> Active, not recruiting | Trial completion date: Oct 2018 --> Mar 2019 | Trial primary completion date: May 2018 --> Jan 2019
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead, yimitasvir (DAG181) / Dongguan HEC TaiGen Biopharma, HEC Pharm
    New P3 trial:  Phase 3 Study of Yimitasvir Phosphate Capsules (clinicaltrials.gov) -  Apr 2, 2018   
    P3,  N=360, Not yet recruiting, 
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Trial completion, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date:  Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (clinicaltrials.gov) -  Mar 8, 2018   
    P4,  N=10000, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | N=6000 --> 10000 | Trial completion date: Dec 2018 --> Mar 2018 | Initiation date: Dec 2016 --> Jan 2015 | Trial primary completion date: Dec 2018 --> Jan 2018
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead, yimitasvir (DAG181) / Dongguan HEC TaiGen Biopharma, HEC Pharm
    New P2 trial:  Phase 2 Study of Yimitasvir Phosphate Capsules (clinicaltrials.gov) -  Mar 8, 2018   
    P2,  N=129, Active, not recruiting, 
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories. (Pubmed Central) -  Feb 17, 2018   
    While sofosbuvir, the only approved nucleotide NS5B inhibitor, has been the backbone of most pangenotypic therapeutic regimens, it has a limitation in those with advanced kidney disease...Globally genotype 3 is a common infection and thus this group with CKD presents a huge unmet need for effective therapies. Since therapy of HCV in renal transplant recipients has been highly successful, it provides an opportunity to expand the use of HCV infected organs in solid organ transplantation.